Enters Australia, with Pilot renamed Hims, the first result of the acquisition integration
HIMS has renamed Pilot, the men's health platform owned by Eucalyptus, which it bought earlier this year, as Hims. It has also launched branded GLP-1 weight-loss drugs (Wegovy and Zepbound) for men in Australia.
Read more
This is the first verifiable result since the Eucalyptus acquisition (rebrand, move onto the HIMS digital platform, reuse user and doctor relationships) and the first substantive step in its international push. The company has set a hard target of $1 billion in annual international revenue within 3 years. The direction is positive: the deal is delivering, internationalisation has broken ground and there is a new growth metric. On earnings quality, however, the read is neutral to slightly negative. Australia copies the low-margin branded GLP-1 model from the US, which points the same way as the fall in gross margin from 76% to 64% and the GAAP net loss of $86.3 million disclosed with Q2 results on 10 Aug. It strengthens the growth story. It is not a profit inflection.
Key evidence
- Official announcement via BusinessWire and StockTitan on 31 Aug: Pilot is renamed Hims with immediate effect, and existing users keep their current treatment plans and doctor relationships.
- Branded GLP-1 weight-loss drugs (Wegovy and Zepbound) launch in Australia at the same time, aimed at men.
- Stated target: annual international revenue of $1 billion within 3 years.
- Tim Doyle, founder and former CEO of Eucalyptus, is now senior vice president of international at HIMS.
- Australia's telehealth market is expected to grow to $2.56 billion by 2034. Nearly 30% of Pilot's patients are in remote or rural areas.
- Until now, 100% of revenue has come from the US. Australia is the first overseas revenue engine and the first Asia-Pacific market.
- This follows the Q2 results of 10 Aug: revenue up 38%, but gross margin fell from 76% to 64% and the GAAP net loss was $86.3 million.
Catalysts to watch
- International revenue figures in coming quarters, to test the timetable of $1 billion in 3 years
- Q4 results: whether the profit jump is delivered remains the key proof point
- Whether the other Eucalyptus brands follow the Pilot-to-Hims integration path
- The stance of Australian regulators and health insurance policy toward telehealth sales of branded GLP-1 drugs
Risks
- Selling Wegovy and Zepbound in Australia replicates the low-margin branded-drug model from the US, which weighs on gross margin.
- Early customer acquisition spending in a new market is heavy, which is negative for near-term earnings.
- Q2 has already swung to a GAAP net loss of $86.3 million, with expansion burning cash up front.
- The core tension is unchanged: fast revenue growth against erosion from both earnings quality and compliance costs.
- Set aside: the law firms Berger Montague and Scott+Scott are investigating the board for 'breach of fiduciary duty' (a prelude to a class action, and not first-hand information).
Sources (2)
- BusinessWire, 31 Aug 2026, official announcement
- StockTitan, 31 Aug 2026
A brief is a lead for our research, not a verified conclusion or advice.